Drug profile · INN
vorasidenib
VORANIGO
vorasidenib (VORANIGO) is a idh1/idh2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
FDA: approved EMA: approved Antineoplastic and immunomodulating agents (L01) L01XM04
US status approved
Patents linked 2
Pipeline programs 0
News articles 0
Drug details — vorasidenib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 2
- Programs
- 0
- Data quality
- 0.84
Quick answer
vorasidenib (VORANIGO) is a idh1/idh2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN vorasidenib
Brand VORANIGO
Mechanism IDH1/IDH2 inhibitor
Target IDH1/IDH2
Therapeutic class Antineoplastic and immunomodulating agents (L01)
Route ORAL
Formulation TABLET
ATC code L01XM04
Mechanism of action
IDH1/IDH2 inhibitor
Primary target: IDH1/IDH2
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Related & competitor drugs
Related patents
Frequently asked questions
What is vorasidenib?
vorasidenib (VORANIGO) is a idh1/idh2 inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vorasidenib?
VORANIGO is a marketed brand name for vorasidenib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vorasidenib?
vorasidenib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.